ALUR
Allurion Technologies Inc.
NYSE · Healthcare · Medical - Devices · US
$1.12
+1.82%Year over year
Reported trailing growth
- Revenue
- -55.5%
- EBITDA
- -72.2%
- EBIT
- +42.3%
- EPS
- —
- Free cash flow
- +48.0%
- Operating cash flow
- +47.4%
Forward estimates
Based on analyst estimates
- Revenue
- -40.5%
- EBITDA
- +82.6%
- EPS
- +83.2%
Three-year CAGR
- Revenue
- -38.1%
- EBITDA
- -24.9%
- EBIT
- +39.9%
- Net income
- -10.0%
- EPS
- -19.1%
- Free cash flow
- +32.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026